Status:
COMPLETED
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Tumors
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this trial is to determine the mass balance, pharmacokinetics, metabolism, and routes and extent of elimination of BMS-582664
Eligibility Criteria
Inclusion
- Histologic/cytologic diagnosis of advanced or metastatic solid tumors
- ECOG 0-2
- 4/6 weeks since prior therapy
Exclusion
- Brain metastases
- Secondary primary malignancy
- Thromboembolic disease requiring full anticoagulation within 6 months
- Inability to swallow or absorb oral therapy
- Uncontrolled hypertension
Key Trial Info
Start Date :
September 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT00435669
Start Date
September 1 2007
End Date
June 1 2008
Last Update
January 22 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195